Your browser doesn't support javascript.
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines.
Bowen, John E; Addetia, Amin; Dang, Ha V; Stewart, Cameron; Brown, Jack T; Sharkey, William K; Sprouse, Kaitlin R; Walls, Alexandra C; Mazzitelli, Ignacio G; Logue, Jennifer K; Franko, Nicholas M; Czudnochowski, Nadine; Powell, Abigail E; Dellota, Exequiel; Ahmed, Kumail; Ansari, Asefa Shariq; Cameroni, Elisabetta; Gori, Andrea; Bandera, Alessandra; Posavad, Christine M; Dan, Jennifer M; Zhang, Zeli; Weiskopf, Daniela; Sette, Alessandro; Crotty, Shane; Iqbal, Najeeha Talat; Corti, Davide; Geffner, Jorge; Snell, Gyorgy; Grifantini, Renata; Chu, Helen Y; Veesler, David.
  • Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Addetia A; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Dang HV; Vir Biotechnology, San Francisco, CA 94158, USA.
  • Stewart C; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Brown JT; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Sharkey WK; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Mazzitelli IG; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.
  • Logue JK; Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Buenos Aires C1121ABG, Argentina.
  • Franko NM; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
  • Czudnochowski N; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
  • Powell AE; Vir Biotechnology, San Francisco, CA 94158, USA.
  • Dellota E; Vir Biotechnology, San Francisco, CA 94158, USA.
  • Ahmed K; Vir Biotechnology, San Francisco, CA 94158, USA.
  • Ansari AS; Departments of Paediatrics and Child Health and Biological and Biomedical Sciences, Aga Khan University, Karachi 74800, Pakistan.
  • Cameroni E; Departments of Paediatrics and Child Health and Biological and Biomedical Sciences, Aga Khan University, Karachi 74800, Pakistan.
  • Gori A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
  • Bandera A; Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Posavad CM; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
  • Dan JM; Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy.
  • Zhang Z; Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Weiskopf D; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
  • Sette A; Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy.
  • Crotty S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
  • Iqbal NT; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • Corti D; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA 92037, USA.
  • Geffner J; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • Snell G; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • Grifantini R; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • Chu HY; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA 92037, USA.
  • Veesler D; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Science ; 377(6608): 890-894, 2022 08 19.
Article in English | MEDLINE | ID: covidwho-1949930
ABSTRACT
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern comprises several sublineages, with BA.2 and BA.2.12.1 having replaced the previously dominant BA.1 and with BA.4 and BA.5 increasing in prevalence worldwide. We show that the large number of Omicron sublineage spike mutations leads to enhanced angiotensin-converting enzyme 2 (ACE2) binding, reduced fusogenicity, and severe dampening of plasma neutralizing activity elicited by infection or seven clinical vaccines relative to the ancestral virus. Administration of a homologous or heterologous booster based on the Wuhan-Hu-1 spike sequence markedly increased neutralizing antibody titers and breadth against BA.1, BA.2, BA.2.12.1, BA.4, and BA.5 across all vaccines evaluated. Our data suggest that although Omicron sublineages evade polyclonal neutralizing antibody responses elicited by primary vaccine series, vaccine boosters may provide sufficient protection against Omicron-induced severe disease.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Science Year: 2022 Document Type: Article Affiliation country: Science.abq0203

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Science Year: 2022 Document Type: Article Affiliation country: Science.abq0203